Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$1.5 - $3.04 $110,400 - $223,744
-73,600 Reduced 28.9%
181,100 $291,000
Q1 2023

May 15, 2023

BUY
$2.8 - $5.46 $713,160 - $1.39 Million
254,700 New
254,700 $738,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $726M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track Lee Ainslie's Portfolio

Track Lee Ainslie Portfolio

Follow Lee Ainslie (Maverick Capital LTD) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.